Mallinckrodt acquired Ikaria from Madison Dearborn-led investor group for ~$2.3B, expanding into neonatal critical care and adding INOMAX (inhaled nitric oxide) drug-device platform. Closed April 16, 2015.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Mixed
Assessment window: 10yr post-close.
Key facts
AnnouncedMar 05, 2015
ClosedApr 16, 2015
Deal value$2.3B
Deal typeAcquisition/Merger
Therapeutic areaHypoxic respiratory failure in term/near-term neonates; pulmonary hypertension
IndicationsHypoxic respiratory failure in term/near-term neonates; pulmonary hypertension
Key assetsINOMAX (inhaled nitric oxide) and delivery device (INOmax DSIR)